A single-arm phase 2 trial of Sitravatinib in advanced well-differentiated/dedifferentiated liposarcoma.

Matthew Ingham Shing M Lee Brian Andrew Van Tine Edwin Choy Jay Oza Sahil D Doshi Liner Ge Peter Oppelt Gregory M Cote Brian Corgiat Naomi Sender Sarah Sta Ana Lavan Panchalingam Emanuel F Petricoin Gary K Schwartz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Sitravatinib provided a progression-free rate at 12 weeks of 41% and meaningful disease control in a subset of patients with advanced, progressive WD/DD LPS.

Keyphrases

multiple sclerosis
inflammatory response
anti inflammatory